Medication-Related Problem Framework

Why it matters

• NAPLEX often rewards the safest pharmacist action, not the most medically comprehensive action.
• Many wrong answers are clinically useful in another setting but are outside pharmacist scope or premature before clarification.
• A single clue—severe allergy, renal impairment, missing indication, dosage-form mismatch, urgent symptom—often determines whether you can proceed or must stop.
• In practice and on exam day, missing the need to hold and clarify causes more harm than missing a minor optimization opportunity.

Key Terms & Must-Know Facts

Key terms

• Best next pharmacist action — the safest, most appropriate action within pharmacist scope based on available data.
• Hold — do not dispense/administer until a safety concern is resolved.
• Clarify — contact prescriber/patient/caregiver to obtain missing or conflicting information.
• Verify — confirm the order is appropriate for indication, patient factors, product, and safety.
• Recommend — suggest a safer or more effective alternative to the prescriber.
• Escalate — urgent referral, emergency activation, or immediate team notification for time-sensitive harm.
• Red flag — finding that changes the action from routine processing to hold/clarify/escalate.
• Scope boundary — limit beyond which the pharmacist should not independently diagnose or prescribe.
• Decisive clue — single case detail that separates the correct option from near-miss distractors.
• Medication-related problem — issue of indication, effectiveness, safety, or adherence.
• Immediate clarification — clarification required before dispensing because delay in resolution could prevent harm.
• Monitoring plan — parameter, frequency, and action threshold after therapy proceeds.

Must-know facts

• When the order is unsafe or incomplete, the best action is usually hold and clarify before dispensing.
• If the stem includes anaphylaxis, severe bleeding, chest pain, stroke symptoms, overdose, or major allergic reaction, think urgent escalation/referral.
• If multiple actions are reasonable, choose the one that fits pharmacist scope and uses currently available data.
• Do not optimize therapy before first addressing an active safety threat.
• A “better long-term drug choice” is not the best next step if the current priority is dose clarification, contraindication review, or urgent referral.
• Missing age, weight, allergies, renal function, or dosage form can convert a routine verification question into a clarification question.
• Distractors often differ by one variable: timing, urgency, authority, or data sufficiency.
• Patient counseling is appropriate only after it is safe to proceed; counseling does not replace clarification of a potentially harmful order.

flowchart TD
A[Order or patient question appears] --> B{Immediate danger?}
B -->|Yes| C[Escalate urgently / refer / activate EMS per setting]
B -->|No| D{Unsafe or incomplete order?}
D -->|Yes| E[Hold and clarify before dispensing]
D -->|No| F{Therapy appropriate but needs optimization?}
F -->|Yes| G[Recommend change + monitor + document]
F -->|No| H[Verify / counsel / dispense]

flowchart TD
A[Need identified] --> B{Can pharmacist act safely with given data?}
B -->|Yes| C[Verify / counsel / recommend / monitor]
B -->|No| D{Need diagnosis or prescribing authority not provided?}
D -->|Yes| E[Clarify with prescriber or refer]
D -->|No| F[Gather missing patient data before proceeding]

flowchart LR
A[Question identified] --> B{Potential harm if dispensed now?}
B -->|Yes| C[Clarify first]
B -->|No| D{Patient can use product correctly?}
D -->|No| E[Counsel on technique / adherence]
D -->|Yes| F[Proceed with verification]

flowchart TD
A[Medication order] --> B[Check patient identifiers]
B --> C[Check allergy and indication]
C --> D[Check age weight renal hepatic status]
D --> E[Check dose route frequency duration]
E --> F{Enough data to verify safely?}
F -->|No| G[Clarify / gather missing data]
F -->|Yes| H[Verify and counsel]

Core content

1.1.2.1 Foundational decision ladder: verify, hold, clarify, recommend, counsel, or escalate

A. Explanation

The core conflict is usually proceed now versus stop first. The resolving rule is simple: if current information suggests immediate patient harm or the order cannot be judged safe, do not proceed as if verification were routine. Instead, hold and clarify, or escalate urgently if there is active clinical instability. See Fig 1. Many stems tempt you to choose a smart recommendation, but the best next action is earlier in the sequence: protect the patient first, then optimize therapy.

Use a six-step mental ladder. First, ask whether there is an emergency. Second, ask whether the order is unsafe or incomplete. Third, ask whether enough patient data exist to verify safely. Fourth, ask whether the issue is optimization rather than immediate safety. Fifth, determine whether counseling can solve the problem. Sixth, document and monitor once the action is taken. See Fig 2.

WHY THIS IS TESTED: exam writers want to see whether you can reject attractive but premature actions. The single finding that resolves many questions is a safety block: severe allergy, dangerous interaction, dose inappropriate for renal function, wrong route, wrong dosage form, duplication, or missing key information.

B. Worked example

A 72-year-old man presents to the pharmacy with a new prescription for trimethoprim-sulfamethoxazole DS 1 tablet by mouth twice daily for 10 days. His profile shows lisinopril 20 mg daily, spironolactone 25 mg daily, type 2 diabetes, heart failure, and chronic kidney disease with last documented CrCl 28 mL/min. He also mentions mild nasal congestion and asks whether vitamin C would help. The tempting wrong move is to counsel on taking the antibiotic with water and continue, because the dose looks familiar and congestion is irrelevant noise.

Reasoning chain: identify task → prescription verification and safety review. Extract key facts → older adult, CKD, ACE inhibitor, spironolactone, TMP-SMX. Apply rule → TMP-SMX can significantly raise potassium; renal function also affects dosing appropriateness. Eliminate distractors → routine counseling is not enough; switching therapy independently is outside scope without authority; dispensing first and monitoring later ignores an active safety block. Verify → best next pharmacist action is to hold and contact the prescriber to clarify safety and recommend an alternative or renal-adjusted plan.

C. Exam trap

D. Checkpoint

Question: A 66-year-old woman with atrial fibrillation, CKD, and hypertension presents with a new order for dabigatran 150 mg by mouth twice daily. Her profile shows verapamil SR 240 mg daily and CrCl 24 mL/min. The prescription is otherwise complete. What is the most appropriate next pharmacist action?

1. A. Dispense dabigatran and counsel on bleeding because the order contains a standard adult dose.
2. B. Hold the prescription and contact the prescriber because renal function and the interacting medication make the current order unsafe.
3. C. Change the prescription to a lower dabigatran dose and dispense because anticoagulation is indicated.
4. D. Recommend adding aspirin for stroke prevention because atrial fibrillation increases thromboembolic risk.

Answer: B.

• A: Tempting because standard doses are familiar; wrong because renal impairment plus verapamil changes safety and the pharmacist should not bypass clarification.
• B: Correct because the issue is not whether anticoagulation is needed, but whether this specific order is safe with current renal function and interaction risk.
• C: Tempting because dose adjustment seems proactive; wrong because changing the prescription independently exceeds scope unless authority is provided.
• D: Tempting because stroke prevention matters; wrong because adding aspirin does not solve the unsafe anticoagulant order and may increase bleeding.

1.1.2.2 Data sufficiency: when missing information changes the answer

A. Explanation

The next conflict is act now versus gather one more decisive fact. The resolving rule: if the missing data point is one that could materially change dose, product, route, or safety, the best next action is to obtain that information before verification. See Fig 5. Common decisive data are age, weight, allergy history, pregnancy status, renal function, hepatic status, current medication list, route feasibility, and indication.

Board-style stems include noise on purpose: a remote surgery, old lab value, mild seasonal symptoms, or a normal blood pressure reading. Those details feel clinical, but they are not always action-driving. What matters is the missing factor that changes whether the order can be safely processed. See Fig 3. For example, amoxicillin suspension quantity without patient age or indication may still be workable, but enoxaparin dose without current weight or renal function is not. A metoprolol tablet order for a patient with a feeding tube raises dosage-form and route questions; counseling alone is not enough.

WHY THIS IS TESTED: NAPLEX tests your ability to recognize that insufficient data is itself a medication-safety problem. Students often overconfidently select a dose, substitute a product, or give counseling when the safer answer is to clarify missing information.

B. Worked example

A 4-year-old child is discharged from urgent care with amoxicillin-clavulanate suspension 600 mg/42.9 mg per 5 mL, “take 7.5 mL by mouth twice daily.” The child’s grandmother drops off the prescription. The profile shows recurrent otitis media, peanut allergy, and a remote rash with cefdinir. Weight is not listed in the community pharmacy system, and the grandmother is unsure of the child’s current weight. The distracting clue is the cefdinir rash, which may tempt you to focus on beta-lactam cross-reactivity alone.

Reasoning chain: identify task → pediatric prescription verification. Extract key facts → high-strength suspension, child, no weight available, possible need for mg/kg assessment. Apply rule → if weight is necessary to determine appropriateness, clarify before dispensing. Eliminate distractors → counseling on reconstitution or diarrhea risk does not solve the dosing uncertainty; substituting a lower volume independently exceeds scope; refusing all penicillins because of a cefdinir rash overreads the allergy clue. Verify → best next pharmacist action is to obtain current weight or confirm the intended dose with the prescriber before dispensing.

C. Exam trap

D. Checkpoint

Question: A 58-year-old man with type 2 diabetes, obesity, and stage 3 CKD brings a new prescription for enoxaparin 120 mg subcutaneously every 12 hours for home treatment. His profile lists no current weight from this admission, and the only recorded value is from 18 months ago. What is the most appropriate next pharmacist action?

1. A. Dispense because twice-daily enoxaparin is a common treatment schedule.
2. B. Clarify the patient’s current weight and renal function before verifying the dose.
3. C. Change the dose to 40 mg daily because obesity increases thrombosis risk.
4. D. Counsel the patient to rotate injection sites and begin therapy immediately.

Answer: B.

• A: Tempting because the schedule looks therapeutic; wrong because dose appropriateness cannot be judged without current patient-specific data.
• B: Correct because weight-based dosing and renal function are decisive for safe verification.
• C: Tempting because prophylactic enoxaparin doses are familiar; wrong because changing to a different regimen without clarification is not appropriate.
• D: Tempting because injection counseling is useful; wrong because counseling cannot replace obtaining critical dosing data.

1.1.2.3 Applied pattern recognition: safety threat first, optimization second

A. Explanation

This section asks you to choose between fixing the biggest danger now and improving therapy later. The resolving rule is priority: address the finding most likely to produce near-term harm before pursuing a guideline refinement. See Fig 3. Examples: duplicate anticoagulants, severe interaction, absolute contraindication, overdose, wrong route, and dosage-form mismatch outrank adherence counseling, nonurgent formulary substitution, or long-term goal optimization.

In stems, the wrong answer often sounds clinically sophisticated: intensify heart-failure therapy, switch to a more guideline-preferred statin, recommend vaccine updates, or address adherence. Those may all be worthwhile, but not before you stop the unsafe order. The pharmacist’s first duty is to prevent medication-related harm. If the patient is unstable or symptomatic, move to escalation; if the order itself is unsafe but the patient is not crashing, hold and clarify.

WHY THIS IS TESTED: learners often chase the most “medical” answer. NAPLEX instead rewards sequencing: what must happen first? When in doubt, choose the option that neutralizes immediate risk while staying within pharmacist scope.

B. Worked example

A 63-year-old woman with atrial fibrillation, coronary artery disease, and osteoarthritis presents for refill synchronization. Her profile shows apixaban 5 mg twice daily, aspirin 81 mg daily, ibuprofen 800 mg three times daily as needed, omeprazole 20 mg daily, and a new prescription for naproxen 500 mg twice daily. She reports occasional heartburn and says she keeps forgetting evening doses of some medicines. The tempting wrong answer is adherence counseling because missed doses are clinically relevant.

Reasoning chain: identify task → best pharmacist action on a new prescription and current profile. Extract key facts → anticoagulant plus aspirin plus high-dose NSAID exposure plus another NSAID being added. Apply rule → combined antithrombotic and NSAID use increases bleeding risk; this active safety issue outranks routine adherence discussion. Eliminate distractors → changing omeprazole dose does not solve the bleed-risk combination; counseling about missed doses is useful but secondary; dispensing naproxen with food is unsafe sequencing. Verify → best next pharmacist action is to hold the NSAID prescription and contact the prescriber regarding bleeding risk and safer analgesic options.

C. Exam trap

D. Checkpoint

Question: A 70-year-old man with HFrEF, diabetes, and chronic atrial fibrillation presents with a prescription for clarithromycin 500 mg by mouth twice daily for pneumonia from urgent care. His profile includes simvastatin 40 mg nightly, digoxin 0.125 mg daily, and warfarin 5 mg daily. INR from two days ago was 2.5. What is the most appropriate next pharmacist action?

1. A. Dispense clarithromycin and counsel on taking the full antibiotic course.
2. B. Contact the prescriber to discuss major interaction risk before dispensing clarithromycin.
3. C. Tell the patient to stop warfarin for the duration of clarithromycin therapy.
4. D. Recommend adding a probiotic to reduce antibiotic-associated diarrhea.

Answer: B.

• A: Tempting because pneumonia treatment should not be delayed; wrong because this specific drug creates major interaction concerns with current therapy.
• B: Correct because the highest-priority issue is interaction-related harm, not routine antibiotic counseling.
• C: Tempting because warfarin interaction is real; wrong because the pharmacist should not independently discontinue prescribed anticoagulation without clarification.
• D: Tempting because it addresses a common adverse effect; wrong because it ignores the more urgent safety conflict.

1.1.2.4 Urgent escalation versus routine pharmacist management

A. Explanation

The conflict here is can the pharmacist handle this routinely, or does the patient need immediate referral? The resolving rule is red-flag symptom severity. See Fig 4. If the patient has signs of anaphylaxis, severe bleeding, chest pain, severe dyspnea, stroke symptoms, opioid overdose, profound hypoglycemia with altered mental status, or other instability, the best next action is not detailed counseling or office-style troubleshooting. It is urgent escalation consistent with pharmacist role and setting.

Do not confuse “serious drug problem” with “emergency.” A dangerous interaction on a prescription usually calls for hold and prescriber contact. A patient currently wheezing after taking amoxicillin, a warfarin patient with active vomiting of blood, or a sedated patient with pinpoint pupils and slowed breathing needs immediate emergency action and referral. See Fig 1. The exam wants you to separate order-level safety management from patient-level acute instability.

WHY THIS IS TESTED: candidates often under-react to red-flag symptoms because they get drawn into drug specifics. The testable pattern is that symptomatic instability changes the action category entirely.

B. Worked example

A 41-year-old woman picks up amoxicillin-clavulanate 875/125 mg twice daily and returns to the counter 10 minutes later with diffuse hives, lip swelling, hoarse voice, and difficulty breathing. She has asthma and hypertension and says she once had a mild rash from a “different antibiotic” years ago. Her husband asks whether diphenhydramine tablets would be enough. The tempting wrong answer is to recommend oral antihistamine and observe, because hives alone can suggest a less severe allergic reaction.

Reasoning chain: identify task → patient triage within pharmacist scope. Extract key facts → recent antibiotic exposure, lip swelling, hoarseness, dyspnea. Apply rule → airway symptoms indicate possible anaphylaxis and require immediate emergency response. Eliminate distractors → counseling about future allergy documentation is important but not first; calling the prescriber about changing antibiotics is delayed sequencing; oral antihistamine alone is inadequate. Verify → best next pharmacist action is to activate emergency response per setting, provide allowed emergency support, and urgently escalate care.

C. Exam trap

D. Checkpoint

Question: A 54-year-old man with chronic back pain, COPD, and depression comes to the pharmacy to pick up oxycodone ER 20 mg every 12 hours. He is difficult to arouse, has slurred speech, and his wife reports he took “extra anxiety pills” about an hour ago. Respiratory rate is visibly slow. What is the most appropriate next pharmacist action?

1. A. Counsel the wife to skip the next oxycodone dose and monitor him at home.
2. B. Urgently escalate care because the patient shows signs of possible overdose and respiratory compromise.
3. C. Refuse to dispense the oxycodone but take no further action because the patient is leaving.
4. D. Recommend taking the oxycodone with food once he is more awake.

Answer: B.

• A: Tempting because dose omission seems practical; wrong because respiratory compromise requires urgent action, not home observation alone.
• B: Correct because the patient is symptomatic now, which changes this from verification to emergency escalation.
• C: Tempting because withholding the medication prevents further exposure; wrong because failing to escalate ignores an active emergency.
• D: Tempting only if one focuses on routine counseling; wrong because the patient is unstable.

1.1.2.5 Communicating the action: what to notice, say, monitor, and document

A. Explanation

Even when you identify the correct action category, you can still miss a NAPLEX question if you choose the wrong communication step. The conflict is silent processing versus explicit safety communication. The resolving rule: the best pharmacist action should usually include a clear statement of the problem, a specific recommendation or request, a monitoring plan, and documentation. See Fig 5. Good answers often sound operational: hold, contact, recommend, counsel, monitor, document.

For the patient, state what is happening and why there is a delay or referral. For the prescriber, communicate the exact concern, the relevant patient factors, and a practical recommendation. For the record, document the interaction and outcome. For monitoring, name a parameter and timeframe. The exam may present several clinically sensible actions; the best one usually has the strongest closed-loop safety behavior.

WHY THIS IS TESTED: entry-level pharmacist practice is not just recognition; it is execution. The testable pattern is that the safest answer often includes both the immediate action and the follow-up responsibility.

B. Worked example

A 78-year-old woman with heart failure, osteoarthritis, and insomnia presents with a new prescription for zolpidem 10 mg nightly. Her medication list includes hydrocodone-acetaminophen as needed, gabapentin 300 mg three times daily, and furosemide 40 mg daily. She reports two falls in the last six months and says she “just needs something strong” because she sleeps poorly. The distracting clue is insomnia severity, which may push you toward rapid dispensing and counseling.

Reasoning chain: identify task → evaluate new prescription and best pharmacist action. Extract key facts → older adult, fall history, multiple CNS depressants, high-risk sedative. Apply rule → the issue is not simply insomnia counseling; there is a safety concern requiring prescriber communication. Eliminate distractors → handing out fall-prevention counseling alone is incomplete; changing the dose independently is outside scope unless authorized; refusing without explanation misses the recommendation step. Verify → best next pharmacist action is to hold and contact the prescriber to discuss fall/CNS depression risk, recommend a safer approach, counsel the patient about the reason for delay, and document the intervention.

C. Exam trap

D. Checkpoint

Question: A 60-year-old patient with gout, hypertension, and CKD receives allopurinol 300 mg by mouth daily as a new start. The profile lists hydrochlorothiazide and a past note of “rash with allopurinol uncertain.” Which option best reflects the most appropriate pharmacist action?

1. A. Dispense immediately and tell the patient rash can occur with many drugs.
2. B. Hold the prescription, clarify the prior reaction and current renal function, communicate the concern to the prescriber, and document the outcome.
3. C. Change the order to febuxostat and dispense because CKD makes allopurinol less desirable.
4. D. Tell the patient to restart the allopurinol only if gout pain worsens.

Answer: B.

• A: Tempting because mild rash can be nonspecific; wrong because the prior reaction and renal considerations are decisive enough to require clarification.
• B: Correct because it combines safe withholding, targeted clarification, prescriber communication, and documentation.
• C: Tempting because it offers an alternative; wrong because the pharmacist should not unilaterally substitute a different prescription medication without authority.
• D: Tempting because it appears cautious; wrong because it provides unsafe unsupervised self-titration and avoids resolving the order problem.

Exam Traps & Differentiators

If the stem says “best next pharmacist action,” think in this order:

• If the stem says active bleeding, think escalate urgently.
• If the stem says dangerous interaction or contraindication, think hold and clarify.
• If the stem says weight/CrCl/allergy details missing, think get the missing decisive fact.
• If the stem says new adherence or affordability barrier without acute safety issue, think counsel/recommend/monitor.
• If the stem says appealing therapy change but no authority, think recommend, do not independently prescribe.

Tables

Algorithm / Approach

Rapid Review

• Unsafe order → hold before you counsel
• Red-flag symptoms → escalate before you clarify routine details
• Missing weight/CrCl/allergy specifics → data gap can be the whole question
• Better long-term therapy → not first if active harm exists now
• Interaction plus stability → usually hold/clarify, not EMS
• Interaction plus instability → escalate urgently
• Pharmacist knows safer alternative → recommend, do not independently prescribe unless authority is stated
• Routine administration question without danger → counsel and monitor
• Old profile value for dose-critical medication → verify whether current value is needed
• Duplicate high-risk therapy → safety problem before adherence problem
• Wrong dosage form for route/feeding tube → product selection issue before dispensing
• Patient asks for OTC relief but has chest pain/SOB/major bleed → referral beats self-care
• Best answer often includes documentation → closed-loop safety behavior
• Most tempting distractor → useful action performed at the wrong time

Self-check quiz

1. A 68-year-old woman with hypertension and CKD brings a prescription for nitrofurantoin 100 mg by mouth twice daily for 5 days. Her profile does not contain a recent renal function value, and the only serum creatinine is from three years ago. She also asks whether cranberry capsules help UTIs. What is the most appropriate next pharmacist action?

1. A. Dispense nitrofurantoin because the duration is standard for uncomplicated cystitis.
2. B. Clarify current renal function before verifying the prescription.
3. C. Recommend cranberry capsules instead of the antibiotic.
4. D. Change the prescription to trimethoprim-sulfamethoxazole and dispense.

2. A 74-year-old man with osteoarthritis, atrial fibrillation, and GERD presents with a new prescription for ibuprofen 800 mg by mouth three times daily. His profile lists rivaroxaban 20 mg daily and aspirin 81 mg daily. He says the knee pain is “really bad today.” What is the best pharmacist action?

1. A. Hold the prescription and contact the prescriber about increased bleeding risk.
2. B. Dispense and counsel him to take ibuprofen with food.
3. C. Tell him to stop rivaroxaban on painful days.
4. D. Recommend doubling the omeprazole dose to prevent bleeding.

3. A 6-year-old child with acute otitis media, mild eczema, and a peanut allergy is prescribed cefdinir suspension 250 mg/5 mL, 6 mL by mouth once daily. The child’s mother does not know the current weight, and the pharmacy profile has no weight entered. The child previously tolerated amoxicillin. What is the most appropriate next pharmacist action?

1. A. Dispense because the child tolerated amoxicillin previously.
2. B. Clarify the child’s current weight or intended dose before dispensing.
3. C. Change the product to tablets because once-daily dosing improves adherence.
4. D. Recommend an OTC antihistamine to reduce the risk of rash.

4. A 59-year-old patient with mechanical heart valve replacement, diabetes, and chronic pain presents with warfarin 5 mg daily refills and a new prescription for metronidazole 500 mg by mouth three times daily. INR yesterday was 2.9. The patient also mentions mild constipation. What is the most appropriate next pharmacist action?

1. A. Dispense metronidazole and suggest more fiber for constipation.
2. B. Contact the prescriber because metronidazole may significantly increase warfarin effect and requires a plan before dispensing.
3. C. Tell the patient to stop warfarin until the antibiotic is finished.
4. D. Switch metronidazole to azithromycin without contacting the prescriber.

5. A 47-year-old woman with asthma, hypertension, and depression returns to the pharmacy 15 minutes after taking her first dose of amoxicillin 500 mg. She has generalized hives, throat tightness, and shortness of breath. Her husband asks which antihistamine to buy. What is the best next pharmacist action?

1. A. Recommend diphenhydramine and observe in the waiting area.
2. B. Urgently escalate care because the patient shows airway involvement after antibiotic exposure.
3. C. Call the prescriber to request doxycycline and send the patient home.
4. D. Advise the patient to drink water because the reaction may be anxiety-related.

6. A 79-year-old woman with heart failure, chronic insomnia, neuropathy, and two falls in the last year presents with a new prescription for zolpidem 10 mg by mouth nightly. Her profile includes gabapentin 300 mg three times daily and hydrocodone-acetaminophen as needed. She says she has been exhausted for weeks and wants the medication tonight. What is the most appropriate next pharmacist action?

1. A. Dispense zolpidem and counsel on using the lowest effective number of nights.
2. B. Hold the prescription and contact the prescriber about fall and CNS depression risk before dispensing.
3. C. Change the dose to zolpidem 5 mg and dispense because the issue is only the starting dose.
4. D. Recommend melatonin and cancel the prescription.

7. A 65-year-old man with atrial fibrillation, CKD, and hypertension presents with a new prescription for dabigatran 150 mg by mouth twice daily. His profile includes verapamil ER 240 mg daily, and current CrCl is 24 mL/min. He says he had mild heartburn last week and wants to start treatment immediately. What is the best pharmacist action?

1. A. Dispense dabigatran and counsel to take it with water.
2. B. Hold the prescription and contact the prescriber because the current order is unsafe with renal impairment and the interacting medication.
3. C. Change the dose to dabigatran 75 mg twice daily and dispense.
4. D. Add famotidine to improve tolerance and proceed with dispensing.

8. A 62-year-old man with coronary artery disease, atrial fibrillation, and chronic low back pain presents with a new prescription for naproxen 500 mg by mouth twice daily. His profile includes apixaban 5 mg twice daily, aspirin 81 mg daily, and pantoprazole 40 mg daily. He reports missing some evening medications recently because of travel. What is the most appropriate next pharmacist action?

1. A. Counsel on adherence to apixaban and dispense the naproxen.
2. B. Hold the naproxen and contact the prescriber because the immediate issue is increased bleeding risk with the current regimen.
3. C. Tell the patient to stop aspirin on days he uses naproxen.
4. D. Increase pantoprazole to twice daily and dispense the naproxen.

Answer key

1. Question 1 — Correct answer: B

A. Tempting because nitrofurantoin and the duration look standard for cystitis. Incorrect for this patient because current renal function can determine whether the drug is appropriate and safe; the single discriminating clue is the absence of a recent renal value in a patient with CKD. Authoritative drug references and product labeling support assessing renal function before use in reduced kidney function settings.

B. Tempting because it delays therapy, which candidates may dislike; correct because the pharmacist needs current renal function to verify nitrofurantoin safely in a CKD patient. The single discriminating clue is outdated renal data only. Supported by FDA labeling and Lexicomp/Clinical Pharmacology renal use guidance.

C. Tempting because the patient asked about cranberry capsules and they sound low risk. Incorrect because supplement counseling does not replace verification of a prescription with a dose-critical safety variable missing. The discriminating clue is that the task is prescription verification, not self-care substitution.

D. Tempting because it offers an alternative antibiotic. Incorrect because independently changing the prescription is outside routine pharmacist authority when no protocol is stated. The single clue is absence of authority to prescribe/substitute therapeutically. Supported by NAPLEX scope expectations and standard pharmacist role boundaries.

2. Question 2 — Correct answer: A

A. Tempting because it seems to delay pain treatment; correct because rivaroxaban plus aspirin plus high-dose ibuprofen markedly increases bleeding risk, so the safest next pharmacist action is to hold and clarify. The discriminating clue is the combination of an anticoagulant and antiplatelet with a new NSAID. Supported by Lexicomp interaction data, AHFS, and standard anticoagulation safety guidance.

B. Tempting because taking NSAIDs with food is common counseling. Incorrect because administration counseling does not neutralize the clinically important bleeding interaction. The single clue is concurrent rivaroxaban and aspirin.

C. Tempting because reducing anticoagulant exposure might reduce bleeding. Incorrect because the pharmacist should not independently interrupt anticoagulation therapy without prescriber direction in this scenario. The discriminating clue is lack of authority and the existence of a safer action: clarify the NSAID order.

D. Tempting because GI protection sounds relevant. Incorrect because a PPI does not solve the core interaction-driven bleeding risk, especially systemic bleeding. The single clue is that the main danger is not merely dyspepsia or ulcer prophylaxis.

3. Question 3 — Correct answer: B

A. Tempting because prior beta-lactam tolerance lowers concern about allergy cross-reactivity. Incorrect because the decisive issue is missing current weight for a pediatric suspension dose assessment, not allergy alone. Supported by pediatric dosing principles in drug references such as Lexicomp and AHFS.

B. Tempting because it can feel administratively inconvenient; correct because current weight may be required to verify appropriateness of the prescribed volume. The single clue is no weight in the profile and mother unable to provide one.

C. Tempting because adherence can improve with solid dosage forms. Incorrect because a 6-year-old may not swallow tablets reliably, and the pharmacist should not switch dosage form without confirming appropriateness and authority. The discriminating clue is the unresolved pediatric dosing question.

D. Tempting because rash concerns are common with cephalosporins. Incorrect because prophylactic antihistamine does not address the actual verification issue. The single clue is absent weight, not a current allergic reaction.

4. Question 4 — Correct answer: B

A. Tempting because metronidazole may be necessary and constipation is an easy counseling point. Incorrect because dispensing without a plan ignores a major warfarin interaction. The discriminating clue is current warfarin therapy with a high-interaction antibiotic. Supported by Lexicomp interaction data and anticoagulation references.

B. Correct because metronidazole can significantly increase warfarin effect, making clarification and monitoring planning the best pharmacist action before dispensing. The single clue is warfarin plus metronidazole in a patient with a mechanical valve, where anticoagulation interruption is also high stakes. Supported by authoritative drug interaction references and anticoagulation guidance.

C. Tempting because it acknowledges the interaction. Incorrect because independently stopping warfarin is unsafe in a mechanical valve patient and exceeds scope. The discriminating clue is the high thromboembolic risk if anticoagulation is interrupted.

D. Tempting because switching antibiotics could avoid the interaction. Incorrect because therapeutic substitution without authorization is not the safest within-scope next step here. The single clue is lack of prescriber clarification.

5. Question 5 — Correct answer: B

A. Tempting because diphenhydramine treats hives and mild allergic reactions. Incorrect because throat tightness and shortness of breath indicate airway involvement and possible anaphylaxis, making observation alone inadequate. Supported by emergency allergy guidance and standard triage principles.

B. Correct because airway symptoms after antibiotic exposure require immediate escalation rather than routine OTC counseling. The single discriminating clue is throat tightness plus dyspnea. Supported by anaphylaxis management standards and pharmacist triage expectations.

C. Tempting because a new antibiotic will eventually be needed. Incorrect because changing antibiotics is not the immediate priority while the patient has possible anaphylaxis. The discriminating clue is acute instability now.

D. Tempting only if one minimizes the symptoms. Incorrect because the symptom cluster is inconsistent with simple anxiety until emergency causes are addressed first. The discriminating clue is generalized hives immediately after drug exposure plus airway symptoms.

6. Question 6 — Correct answer: B

A. Tempting because zolpidem is indicated for insomnia and counseling on limited use sounds prudent. Incorrect because in this patient, prior falls and concurrent CNS depressants create a safety concern that should be addressed before dispensing. The single clue is the fall history plus gabapentin and opioid exposure. Supported by Beers-type geriatric safety considerations and Lexicomp warnings.

B. Correct because the best pharmacist action is to hold and contact the prescriber about fall/CNS depression risk before dispensing. The single clue is not just age, but age plus falls plus interacting sedating agents. Supported by authoritative drug references and geriatric medication safety sources.

C. Tempting because lower doses may be used in older adults. Incorrect because independently changing the dose still exceeds scope when the safety issue itself has not been discussed with the prescriber. The discriminating clue is absence of authorization to alter the prescription.

D. Tempting because melatonin may be safer. Incorrect because canceling the prescription independently is not the pharmacist’s role here; the appropriate action is prescriber clarification and recommendation. The single clue is that the pharmacist should recommend, not unilaterally replace therapy.

7. Question 7 — Correct answer: B

A. Tempting because anticoagulation should begin and heartburn is a minor side issue. Incorrect because the current dabigatran regimen is unsafe in the setting of significant renal impairment and an interacting medication. The single clue is CrCl 24 mL/min with verapamil on the profile. Supported by FDA labeling, Lexicomp, and Clinical Pharmacology.

B. Correct because the pharmacist should hold the prescription and contact the prescriber; the key issue is not whether anticoagulation is needed, but whether this order is safe as written. The single discriminating clue is renal impairment plus verapamil. Supported by labeling and drug interaction references.

C. Tempting because it recognizes the need for dose adjustment. Incorrect because changing the dose independently is not the best within-scope next step unless authority is provided. The discriminating clue is that clarification with the prescriber is still required.

D. Tempting because acid suppression may help dabigatran-related dyspepsia. Incorrect because tolerance management does not solve the regimen’s safety problem. The single clue is that heartburn is noise, while CrCl and verapamil are decisive.

8. Question 8 — Correct answer: B

A. Tempting because missed apixaban doses raise stroke risk and adherence counseling is appropriate in atrial fibrillation. Incorrect because the immediate issue is adding naproxen to apixaban plus aspirin, which creates a current bleeding hazard. The single clue is the new NSAID in a patient already on dual bleeding-risk therapy. Supported by Lexicomp and anticoagulation safety references.

B. Correct because the best next pharmacist action is to hold the naproxen and contact the prescriber about the increased bleeding risk. The single discriminating clue is the current antithrombotic regimen plus new NSAID order. Supported by authoritative interaction references and guideline-based safety practice.

C. Tempting because reducing one bleeding-risk drug seems logical. Incorrect because the pharmacist should not independently modify antiplatelet therapy in this patient without clarification. The single clue is lack of authority and unresolved indication for aspirin.

D. Tempting because GI protection sounds relevant. Incorrect because pantoprazole intensification does not remove the systemic bleeding risk from the regimen. The single clue is that the risk is broader than GI irritation alone.